Lipoprotein (a)(Lp (a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to
apolipoprotein (a). Increased Lp (a) levels are an independent, heritable causal risk factor …

Abstract Lipoprotein (a)[Lp (a)], a distinct lipoprotein class, has become a major focus for
cardiovascular research. This review is written in light of the recent guideline and consensus …

Background: Elevated lipoprotein (a)[Lp (a)] is a common risk factor for cardiovascular
disease outcomes with unknown mechanisms. We examined its potential role in identifying …

Elevated concentration of lipoprotein (a)[Lp (a)] is an independent risk factor for
atherosclerotic cardiovascular disease, including coronary artery disease, stroke, peripheral …

Abstract Purpose of the Review High-density lipoproteins (HDL) are responsible for the
transport in plasma of a large fraction of circulating lipids, in part from tissue mobilization …

There is currently growing attention being paid to the role of elevated triglycerides (TGs) as
important mediators of residual atherosclerotic cardiovascular disease (ASCVD) risk. This …

Dyslipidemia and cardiovascular complications are comorbidities of nonalcoholic fatty liver
disease (NAFLD), which ranges from simple steatosis to nonalcoholic steatohepatitis …

This review focuses on antisense oligonucleotides and small interfering ribonucleic acid
therapies approved or under development for the management of lipid disorders. Recent …

Abstract Purpose of Review Atherosclerotic cardiovascular disease (ASCVD) is still the
leading cause of death worldwide. Despite excellent pharmacological approaches, clinical …

The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo
identified an active compound (compactin) that inhibited cholesterol biosynthesis from the …